Home LiteratureArticle Details
PMID: 2295701 Published · ppublish English Case Reports Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Frameshift mutation near the 3' end of the COL1A1 gene of type I collagen predicts an elongated Pro alpha 1(I) chain and results in osteogenesis imperfecta type I.

The Journal of clinical investigation ·Vol. 85 ·No. 1 ·1990-01-00 ·Pages 282-90

Willing MC, Cohn DH, Byers PH

Abstract

Osteogenesis imperfecta (OI) is a heterogeneous disorder of type I collagen of which OI type I, an autosomal dominant condition, is the mildest and most common form. Affected individuals have blue sclerae, normal stature, bone fragility without significant deformity and osteopenia. Fibroblasts from most affected individuals produce about half the expected amount of structurally normal type I collagen as a result of decreased synthesis of one of its constituent chains, pro alpha 1(I), but the nature of the mutations which result in OI type I are unknown. We describe a three generation family with OI type I in which all affected members have one normal COL1A1 allele and another from which the intragenic Eco RI restriction site near the 3' end of the gene is missing. Amplification by polymerase chain reaction and sequence determination of the normal allele and of the mutant allele in the domain that normally contains the Eco RI site demonstrated a 5-bp deletion from the mutant allele. The deletion changes the translational reading-frame beginning at the Eco RI site and predicts the synthesis of a pro alpha 1(I) chain that extends 84 amino acids beyond the normal termination. Although the mutant pro alpha 1(I) chain is synthesized in an in vitro translation system, we are unable to detect its presence in intact cells, suggesting that it is unstable and rapidly destroyed in one of the cell's degradative pathways. Our analysis of individuals with OI type I from 20 families indicates that this is a unique mutation and suggests that the phenotype can result from multiple mechanisms that decrease the synthesis of normal type I procollagen molecules, including those that alter protein stability.

MeSH Terms
Adult Alleles Amino Acid Sequence Base Sequence Cells, Cultured Cloning, Molecular Collagen/genetics Deoxyribonuclease EcoRI Female Genes Humans Introns Macromolecular Substances Male Molecular Sequence Data Mutation Oligonucleotide Probes Osteogenesis Imperfecta/genetics,metabolism Pedigree Polymerase Chain Reaction Reference Values Restriction Mapping Skin/metabolism
Chemicals
Macromolecular Substances Oligonucleotide Probes Collagen Deoxyribonuclease EcoRI
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Willing M C
Department of Pediatrics, University of Washington, Seattle 98195.
Cohn D H
Byers P H
References (52)
52 references, click to expand
  1. Clinical variability of osteogenesis imperfecta reflecting molecular heterogeneity: cysteine substitutions in the alpha 1(I) collagen chain producing lethal and mild forms.
    J Biol Chem. 1986 Jul 5;261(19):8958-64 PMID: 3722184
  2. Oligomerization is essential for transport of vesicular stomatitis viral glycoprotein to the cell surface.
    Cell. 1986 Sep 12;46(6):929-37 PMID: 3019557
  3. Expression of wild-type and mutant forms of influenza hemagglutinin: the role of folding in intracellular transport.
    Cell. 1986 Sep 12;46(6):939-50 PMID: 3757030
  4. Osteogenesis imperfecta type IV: evidence of abnormal triple helical structure of type I collagen.
    Hum Genet. 1986 Sep;74(1):47-53 PMID: 3759085
  5. Assembly of influenza hemagglutinin trimers and its role in intracellular transport.
    J Cell Biol. 1986 Oct;103(4):1179-91 PMID: 2429970
  6. Osteogenesis imperfecta type IV. Biochemical confirmation of genetic linkage to the pro alpha 2(I) gene of type I collagen.
    J Clin Invest. 1986 Dec;78(6):1449-55 PMID: 3782466
  7. Mutations linked to the pro alpha 2(I) collagen gene are responsible for several cases of osteogenesis imperfecta type I.
    J Med Genet. 1986 Oct;23(5):411-6 PMID: 3023615
  8. Lethal perinatal osteogenesis imperfecta due to the substitution of arginine for glycine at residue 391 of the alpha 1(I) chain of type I collagen.
    J Biol Chem. 1987 May 25;262(15):7021-7 PMID: 3108247
  9. Analysis of cytoplasmic and nuclear messenger RNA in fibroblasts from patients with type I osteogenesis imperfecta.
    Methods Enzymol. 1987;145:223-35 PMID: 3474490
  10. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
    Anal Biochem. 1987 Apr;162(1):156-9 PMID: 2440339
  11. Peptide analysis of collagen produced from cDNA by transcription and translation in vitro.
    Biochem J. 1987 Jul 15;245(2):393-8 PMID: 3663165
  12. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.
    Science. 1988 Jan 29;239(4839):487-91 PMID: 2448875
  13. A frameshift mutation results in a truncated alpha 1-antitrypsin that is retained within the rough endoplasmic reticulum.
    J Biol Chem. 1988 May 25;263(15):7330-5 PMID: 3259232
  14. Arginine for glycine substitution in the triple-helical domain of the products of one alpha 2(I) collagen allele (COL1A2) produces the osteogenesis imperfecta type IV phenotype.
    J Biol Chem. 1988 Jun 5;263(16):7734-40 PMID: 2897363
  15. Heterozygosity for a large deletion in the alpha 2(I) collagen gene has a dramatic effect on type I collagen secretion and produces perinatal lethal osteogenesis imperfecta.
    J Biol Chem. 1988 Jun 15;263(17):8398-404 PMID: 3372533
  16. Degradation from the endoplasmic reticulum: disposing of newly synthesized proteins.
    Cell. 1988 Jul 15;54(2):209-20 PMID: 3292055
  17. Substitution of cysteine for glycine within the carboxyl-terminal telopeptide of the alpha 1 chain of type I collagen produces mild osteogenesis imperfecta.
    J Biol Chem. 1988 Oct 15;263(29):14605-7 PMID: 3170557
  18. Osteogenesis imperfecta. The position of substitution for glycine by cysteine in the triple helical domain of the pro alpha 1(I) chains of type I collagen determines the clinical phenotype.
    J Clin Invest. 1989 Oct;84(4):1206-14 PMID: 2794057
  19. The molecular defect in an autosomal dominant form of osteogenesis imperfecta. Synthesis of type I procollagen containing cysteine in the triple-helical domain of pro-alpha 1(I) chains.
    J Biol Chem. 1986 Jul 5;261(19):9056-64 PMID: 3722186
  20. Detection of specific sequences among DNA fragments separated by gel electrophoresis.
    J Mol Biol. 1975 Nov 5;98(3):503-17 PMID: 1195397
  21. Haemoglobin Constant Spring--a chain termination mutant?
    Nature. 1971 Dec 10;234(5328):337-40 PMID: 4944483
  22. Fine structural analysis of the human pro-alpha 1 (I) collagen gene. Promoter structure, AluI repeats, and polymorphic transcripts.
    J Biol Chem. 1985 Feb 25;260(4):2315-20 PMID: 2857713
  23. Intron-mediated recombination may cause a deletion in an alpha 1 type I collagen chain in a lethal form of osteogenesis imperfecta.
    Proc Natl Acad Sci U S A. 1985 May;82(9):2870-4 PMID: 3857621
  24. Subtle structural alterations in the chains of type I procollagen produce osteogenesis imperfecta type II.
    Nature. 1985 Jul 25-31;316(6026):363-6 PMID: 4022126
  25. Diminished type I collagen synthesis and reduced alpha 1(I) collagen messenger RNA in cultured fibroblasts from patients with dominantly inherited (type I) osteogenesis imperfecta.
    J Clin Invest. 1985 Aug;76(2):604-11 PMID: 4031065
  26. Use of a mixture of proteinase-free collagenases for the specific assay of radioactive collagen in the presence of other proteins.
    Biochemistry. 1971 Mar 16;10(6):988-94 PMID: 4323854
  27. Altered relation of two collagen types in osteogenesis imperfecta.
    N Engl J Med. 1977 May 26;296(21):1200-3 PMID: 857159
  28. Messenger RNA structure: compatibility of hairpin loops with protein sequence.
    Science. 1972 Mar 17;175(4027):1264-6 PMID: 5061249
  29. Nucleotide sequence of the gene coding for the bacteriophage MS2 coat protein.
    Nature. 1972 May 12;237(5350):82-8 PMID: 4555447
  30. Partial nucleotide sequence of 16S ribosomal RNA from E. coli.
    Nat New Biol. 1972 Sep 6;239(88):1-5 PMID: 4562230
  31. Human alpha-chain globin messenger: prediction of a nucleotide sequence.
    Biochem Biophys Res Commun. 1973 Oct 1;54(3):894-8 PMID: 4753197
  32. Haemoglobin Icaria, a new chain-termination mutant with causes alpha thalassaemia.
    Nature. 1974 Sep 20;251(5472):245-7 PMID: 4422784
  33. DNA sequencing with chain-terminating inhibitors.
    Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7 PMID: 271968
  34. Genetic heterogeneity in osteogenesis imperfecta.
    J Med Genet. 1979 Apr;16(2):101-16 PMID: 458828
  35. A system for shotgun DNA sequencing.
    Nucleic Acids Res. 1981 Jan 24;9(2):309-21 PMID: 6259625
  36. Type I osteogenesis imperfecta: a nonfunctional allele for pro alpha 1 (I) chains of type I procollagen.
    Proc Natl Acad Sci U S A. 1982 Jun;79(12):3838-42 PMID: 6954526
  37. Cloning and characterization of five overlapping cDNAs specific for the human pro alpha 1(I) collagen chain.
    Nucleic Acids Res. 1982 Oct 11;10(19):5925-34 PMID: 6183642
  38. Abnormal alpha 2-chain in type I collagen from a patient with a form of osteogenesis imperfecta.
    J Clin Invest. 1983 Mar;71(3):689-97 PMID: 6826730
  39. Post-translational fate of variant MOPC 315 lambda chains in Xenopus oocytes and mouse myeloma cells.
    Eur J Biochem. 1983 Apr 15;132(1):131-8 PMID: 6404626
  40. The molecular defect in a nonlethal variant of osteogenesis imperfecta. Synthesis of pro-alpha 2(I) chains which are not incorporated into trimers of type I procollagen.
    J Biol Chem. 1983 Dec 25;258(24):15192-7 PMID: 6418743
  41. An abnormal collagen alpha chain containing cysteine in autosomal dominant osteogenesis imperfecta.
    Br Med J (Clin Res Ed). 1984 Jan 14;288(6411):112-3 PMID: 6419811
  42. Hematologic and biosynthetic studies in homozygous hemoglobin Constant Spring.
    J Clin Invest. 1984 Jun;73(6):1673-82 PMID: 6725554
  43. "A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum.
    Anal Biochem. 1984 Feb;137(1):266-7 PMID: 6329026
  44. Lysosomal function in the degradation of defective collagen in cultured lung fibroblasts.
    Biochemistry. 1984 May 8;23(10):2134-8 PMID: 6375717
  45. Cysteine in the triple-helical domain of one allelic product of the alpha 1(I) gene of type I collagen produces a lethal form of osteogenesis imperfecta.
    J Biol Chem. 1984 Sep 10;259(17):11129-38 PMID: 6469997
  46. Osteogenesis imperfecta: cloning of a pro-alpha 2(I) collagen gene with a frameshift mutation.
    J Biol Chem. 1984 Nov 10;259(21):12941-4 PMID: 6092353
  47. DNA and chromatin structure of the human alpha 1 (I) collagen gene.
    J Biol Chem. 1984 Dec 10;259(23):14906-13 PMID: 6094581
  48. A short amino acid sequence able to specify nuclear location.
    Cell. 1984 Dec;39(3 Pt 2):499-509 PMID: 6096007
  49. Altered triple helical structure of type I procollagen in lethal perinatal osteogenesis imperfecta.
    J Biol Chem. 1985 Feb 10;260(3):1734-42 PMID: 2981871
  50. Osteogenesis imperfecta is linked to both type I collagen structural genes.
    Lancet. 1986 Jul 12;2(8498):69-72 PMID: 2873381
  51. Biosynthesis, processing, and secretion of M and Z variant human alpha 1-antitrypsin.
    J Biol Chem. 1986 Jul 25;261(21):9979-89 PMID: 3015914
  52. The spectrum of beta-thalassemia genes in China and Southeast Asia.
    Blood. 1986 Oct;68(4):964-6 PMID: 2875755
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1990-01-00
Pages
282-90
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC296416
Subset
IM
Grants
NIAMS NIH HHS · AR-21557 · United States
NIGMS NIH HHS · GM-15253 · United States
Databases
GENBANK
M32790, M32798
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com